ClinicalTrials.Veeva

Menu

Paracetamol for Cancer Pain

H

Haraldsplass Deaconess Hospital

Status and phase

Unknown
Phase 4

Conditions

Advanced Cancer
Opioid Use, Unspecified

Treatments

Drug: paracetamol
Drug: placebo tablets

Study type

Interventional

Funder types

Other

Identifiers

NCT01313247
Par 06-0045

Details and patient eligibility

About

Randomised, double-blind placebo controlled cross-over trial

Main goal:

Optimize the medical pain treatment for patients with advanced cancer disease

Study goal:

Measure paracetamol's additional analgesic effect in a situation where the patient is concomitantly treated with oral opioids eqv. morphine > 100 mg/d.

Full description

National multicenter study with an intention to include 50 patients. 6 days treatment, 3d in each arm. Mean pain score last 24 h: NRS =/> 4 All drug treatment constant during the study period. The participants are allowed to take as much rescue opioids as necessary to have adequate relief.

Paracetamol/ placebo given orally 1000 mg x 4 daily, three days in each arm, direct crossover.

Daily scoring of pain relief, ESAS, overall satisfaction and rescue medication.

Enrollment

50 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adults (> 18 years) of both sexes
  • Diagnosed with advanced cancer disease
  • Ongoing medicinal pain relief treatment in stable dosing with oral opiates equivalent to > 100 mg oral morphine daily
  • NRS median pain score last 24 hrs > 4
  • Able to take tablets (paracetamol) orally

Exclusion criteria

  • Mental or physical deficiency precluding data collection.
  • Reduced liver function judged with bilirubin, INR and transaminases
  • Anticoagulation with warfarin
  • Ongoing use of NSAIDs or 5-HT3 antagonists, or use of such drugs last week
  • Ongoing palliative radiation treatment or radiation treatment during the last 4 weeks.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Quadruple Blind

50 participants in 2 patient groups, including a placebo group

Placebo pills
Placebo Comparator group
Description:
Placebo tablets resembling paracetamol 500 mg are given as alternative 2 tablets 4 times daily
Treatment:
Drug: placebo tablets
oral paracetamol 4 g daily
Active Comparator group
Description:
Patients are given 2 tablets of 500 mg paracetamol on a regular basis 4 times daily
Treatment:
Drug: paracetamol

Trial contacts and locations

1

Loading...

Central trial contact

Jan Henrik Rosland, MD, PhD; Sindre Hoel, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems